CoChat

p53/MDM2 signaling pathway in aging, senescence and tumorigenesis

Huang, Youyi, Che, Xiaofang, Wang, Peter W., Qu, Xiujuan · 2024 · Seminars in Cancer Biology
Cited by 94

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

A wealth of evidence has emerged that there is an association between aging, senescence and tumorigenesis. Senescence, a biological process by which cells cease to divide and enter a status of permanent cell cycle arrest, contributes to aging and aging-related diseases, including cancer. Aging populations have the higher incidence of cancer due to a lifetime of exposure to cancer-causing agents, reduction of repairing DNA damage, accumulated genetic mutations, and decreased immune system efficiency. Cancer patients undergoing cytotoxic therapies, such as chemotherapy and radiotherapy, accelerate aging. There is growing evidence that p53/MDM2 (murine double minute 2) axis is critically involved in regulation of aging, senescence and oncogenesis. Therefore, in this review, we describe the functions and mechanisms of p53/MDM2-mediated senescence, aging and carcinogenesis. Moreover, we highlight the small molecular inhibitors, natural compounds and PROTACs (proteolysis targeting chimeras) that target p53/MDM2 pathway to influence aging and cancer. Modification of p53/MDM2 could be a potential strategy for treatment of aging, senescence and tumorigenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2024.05.001

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 155

  1. Martin, 1996, Genetic analysis of ageing: role of oxidative damage and environmental stresses, Nat. Genet, 13, 25, 10.1038/ng0596-25 · DOI · Paper page
  2. Partridge, 2002, Mechanisms of ageing: public or private?, Nat. Rev. Genet, 3, 165, 10.1038/nrg753 · DOI · Paper page
  3. Melzer, 2020, The genetics of human ageing, Nat. Rev. Genet, 21, 88, 10.1038/s41576-019-0183-6 · DOI · Paper page
  4. Vitale, 2013, Oxidative stress and the ageing endocrine system, Nat. Rev. Endocrinol., 9, 228, 10.1038/nrendo.2013.29 · DOI · Paper page
  5. Benz, 2008, Ageing, oxidative stress and cancer: paradigms in parallax, Nat. Rev. Cancer, 8, 875, 10.1038/nrc2522 · DOI · Paper page
  6. Zhang, 2020, The ageing epigenome and its rejuvenation, Nat. Rev. Mol. Cell Biol., 21, 137, 10.1038/s41580-019-0204-5 · DOI · Paper page
  7. Ogrodnik, 2023, The meaning of adaptation in aging: insights from cellular senescence, epigenetic clocks and stem cell alterations, Nat. Aging, 3, 766, 10.1038/s43587-023-00447-5 · DOI
  8. Bitencourt, 2024, Subcellular structure, heterogeneity, and plasticity of senescent cells, Aging Cell, 10.1111/acel.14154 · DOI · Paper page
  9. Pizzul, 2023, The multistep path to replicative senescence onset: zooming on triggering and inhibitory events at telomeric DNA, Front Cell Dev. Biol., 11, 10.3389/fcell.2023.1250264 · DOI
  10. Larsson, 2011, Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence, Semin Cancer Biol., 21, 367, 10.1016/j.semcancer.2011.10.005 · DOI
  11. Guo, 2022, Aging and aging-related diseases: from molecular mechanisms to interventions and treatments, Signal Transduct. Target Ther., 7, 391, 10.1038/s41392-022-01251-0 · DOI · Paper page
  12. Lieber, 2004, Ageing, repetitive genomes and DNA damage, Nat. Rev. Mol. Cell Biol., 5, 69, 10.1038/nrm1281 · DOI
  13. Muss, 2020, p16 a biomarker of aging and tolerance for cancer therapy, Transl. Cancer Res, 9, 5732, 10.21037/tcr.2020.03.39 · DOI · Paper page
  14. LaPak, 2014, The molecular balancing act of p16(INK4a) in cancer and aging, Mol. Cancer Res, 12, 167, 10.1158/1541-7786.MCR-13-0350 · DOI · Paper page
  15. Kennedy, 2014, RB and lamins in cell cycle regulation and aging, Adv. Exp. Med Biol., 773, 127, 10.1007/978-1-4899-8032-8_6 · DOI
  16. Fu, 2023, Targeting mTOR for anti-aging and anti-cancer therapy, Molecules, 28, 10.3390/molecules28073157 · DOI
  17. Ou, 2018, DNA damage responses and p53 in the aging process, Blood, 131, 488, 10.1182/blood-2017-07-746396 · DOI · Paper page
  18. Yi, 2010, SIRT1 and p53, effect on cancer, senescence and beyond, Biochim Biophys. Acta, 1804, 1684, 10.1016/j.bbapap.2010.05.002 · DOI · Paper page
  19. Vazquez, 2008, The genetics of the p53 pathway, apoptosis and cancer therapy, Nat. Rev. Drug Discov., 7, 979, 10.1038/nrd2656 · DOI · Paper page
  20. Chang, 1995, Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein, J. Biol. Chem., 270, 25014, 10.1074/jbc.270.42.25014 · DOI · Paper page
  21. Liu, 2003, The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein, J. Biol. Chem., 278, 17557, 10.1074/jbc.M210696200 · DOI · Paper page
  22. Scoumanne, 2005, Structural basis for gene activation by p53 family members, Cancer Biol. Ther., 4, 1178, 10.4161/cbt.4.11.2254 · DOI
  23. Silva, 2013, Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor, Biosci. Rep., 33, 10.1042/BSR20130065 · DOI · Paper page
  24. Dikic, 2023, An expanded lexicon for the ubiquitin code, Nat. Rev. Mol. Cell Biol., 24, 273, 10.1038/s41580-022-00543-1 · DOI · Paper page
  25. Popovic, 2014, Ubiquitination in disease pathogenesis and treatment, Nat. Med, 20, 1242, 10.1038/nm.3739 · DOI · Paper page
  26. Zheng, 2023, Elucidating the role of ubiquitination and deubiquitination in osteoarthritis progression, Front Immunol., 14, 1217466, 10.3389/fimmu.2023.1217466 · DOI
  27. Liu, 2022, Targeting matrix metalloproteinases by E3 ubiquitin ligases as a way to regulate the tumor microenvironment for cancer therapy, Semin Cancer Biol., 86, 259, 10.1016/j.semcancer.2022.06.004 · DOI
  28. Wang, 2022, Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy, Semin Cancer Biol., 87, 84, 10.1016/j.semcancer.2022.11.002 · DOI
  29. Wang, 2014, Roles of F-box proteins in cancer, Nat. Rev. Cancer, 14, 233, 10.1038/nrc3700 · DOI · Paper page
  30. Senft, 2018, Ubiquitin ligases in oncogenic transformation and cancer therapy, Nat. Rev. Cancer, 18, 69, 10.1038/nrc.2017.105 · DOI · Paper page
  31. Dobbelstein, 2020, Mdm2: Open questions, Cancer Sci., 111, 2203, 10.1111/cas.14433 · DOI · Paper page
  32. Tan, 2017, Anatomy of Mdm2 and Mdm4 in evolution, J. Mol. Cell Biol., 9, 3, 10.1093/jmcb/mjx002 · DOI · Paper page
  33. Lindstrom, 2007, Putting a finger on growth surveillance: insight into MDM2 zinc finger-ribosomal protein interactions, Cell Cycle, 6, 434, 10.4161/cc.6.4.3861 · DOI · Paper page
  34. Mendoza, 2014, The MDM2 gene family, Biomol. Concepts, 5, 9, 10.1515/bmc-2013-0027 · DOI · Paper page
  35. O'Keefe, 2003, Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination, Mol. Cell Biol., 23, 6396, 10.1128/MCB.23.18.6396-6405.2003 · DOI · Paper page
  36. Moqri, 2023, Biomarkers of aging for the identification and evaluation of longevity interventions, Cell, 186, 3758, 10.1016/j.cell.2023.08.003 · DOI · Paper page
  37. Zhavoronkov, 2019, Deep biomarkers of aging and longevity: from research to applications, Aging (Albany NY), 11, 10771, 10.18632/aging.102475 · DOI · Paper page
  38. de Magalhaes, 2024, Distinguishing between driver and passenger mechanisms of aging, Nat. Genet, 56, 204, 10.1038/s41588-023-01627-0 · DOI
  39. Lin, 2024, MDMX in Cancer: A Partner of p53 and a p53-Independent Effector, Biologics, 18, 61
  40. Aguilar, 2022, Therapeutic strategies to activate p53, Pharm. (Basel), 16
  41. Dumble, 2004, Insights into aging obtained from p53 mutant mouse models, Ann. N. Y Acad. Sci., 1019, 171, 10.1196/annals.1297.027 · DOI · Paper page
  42. Gentry, 2005, Complicating the role of p53 in aging, Aging Cell, 4, 157, 10.1111/j.1474-9726.2005.00154.x · DOI · Paper page
  43. Garcia-Cao, 2002, Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally, EMBO J., 21, 6225, 10.1093/emboj/cdf595 · DOI · Paper page
  44. Liu, 2010, Puma is required for p53-induced depletion of adult stem cells, Nat. Cell Biol., 12, 993, 10.1038/ncb2100 · DOI · Paper page
  45. Li, 2016, Loss of p53-mediated cell-cycle arrest, senescence and apoptosis promotes genomic instability and premature aging, Oncotarget, 7, 11838, 10.18632/oncotarget.7864 · DOI · Paper page
  46. Maor-Nof, 2021, p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR), Cell, 184, 689, 10.1016/j.cell.2020.12.025 · DOI · Paper page
  47. Morganti, 2022, NPM1 ablation induces HSC aging and inflammation to develop myelodysplastic syndrome exacerbated by p53 loss, EMBO Rep., 23, 10.15252/embr.202154262 · DOI
  48. Lessel, 2017, Dysfunction of the MDM2/p53 axis is linked to premature aging, J. Clin. Invest, 127, 3598, 10.1172/JCI92171 · DOI · Paper page
  49. Itahana, 2007, Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation, Cancer Cell, 12, 355, 10.1016/j.ccr.2007.09.007 · DOI · Paper page
  50. Pant, 2016, Distinct downstream targets manifest p53-dependent pathologies in mice, Oncogene, 35, 5713, 10.1038/onc.2016.111 · DOI · Paper page
  51. Pant, 2013, The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity, Genes Dev., 27, 1857, 10.1101/gad.227249.113 · DOI · Paper page
  52. Tollini, 2014, Regulation of p53 by Mdm2 E3 ligase function is dispensable in embryogenesis and development, but essential in response to DNA damage, Cancer Cell, 26, 235, 10.1016/j.ccr.2014.06.006 · DOI · Paper page
  53. Soussi, 2007, Shaping genetic alterations in human cancer: the p53 mutation paradigm, Cancer Cell, 12, 303, 10.1016/j.ccr.2007.10.001 · DOI · Paper page
  54. Attardi, 2005, Probing p53 biological functions through the use of genetically engineered mouse models, Mutat. Res, 576, 4, 10.1016/j.mrfmmm.2004.08.022 · DOI
  55. Lavigueur, 1989, High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene, Mol. Cell Biol., 9, 3982
  56. Lee, 1994, Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice, Oncogene, 9, 3731
  57. Harvey, 1995, A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice, Nat. Genet, 9, 305, 10.1038/ng0395-305 · DOI · Paper page
  58. Li, 1997, neu/ERBB2 cooperates with p53–172 H during mammary tumorigenesis in transgenic mice, Mol. Cell Biol., 17, 3155, 10.1128/MCB.17.6.3155 · DOI · Paper page
  59. Klein, 2000, Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant, Oncogene, 19, 5329, 10.1038/sj.onc.1203941 · DOI
  60. Duan, 2002, Lung-specific expression of human mutant p53–273 H is associated with a high frequency of lung adenocarcinoma in transgenic mice, Oncogene, 21, 7831, 10.1038/sj.onc.1205909 · DOI
  61. Yin, 1998, Control of mouse hepatocyte proliferation and ploidy by p53 and p53ser246 mutation in vivo, Hepatology, 27, 73, 10.1002/hep.510270113 · DOI
  62. Ghebranious, 1998, The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice, Hepatology, 27, 967, 10.1002/hep.510270411 · DOI
  63. Donehower, 1992, Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours, Nature, 356, 215, 10.1038/356215a0 · DOI · Paper page
  64. Purdie, 1994, Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene, Oncogene, 9, 603
  65. Tsukada, 1993, Enhanced proliferative potential in culture of cells from p53-deficient mice, Oncogene, 8, 3313
  66. Armstrong, 1995, High-frequency developmental abnormalities in p53-deficient mice, Curr. Biol., 5, 931, 10.1016/S0960-9822(95)00183-7 · DOI · Paper page
  67. Sah, 1995, A subset of p53-deficient embryos exhibit exencephaly, Nat. Genet, 10, 175, 10.1038/ng0695-175 · DOI · Paper page
  68. Venkatachalam, 1998, Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation, EMBO J., 17, 4657, 10.1093/emboj/17.16.4657 · DOI · Paper page
  69. Venkatachalam, 2001, Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing, Toxicol. Pathol., 29, 147, 10.1080/019262301753178555 · DOI · Paper page
  70. Harvey, 1993, Genetic background alters the spectrum of tumors that develop in p53-deficient mice, FASEB J., 7, 938, 10.1096/fasebj.7.10.8344491 · DOI · Paper page
  71. Kuperwasser, 2000, Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome, Am. J. Pathol., 157, 2151, 10.1016/S0002-9440(10)64853-5 · DOI · Paper page
  72. Jonkers, 2001, Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer, Nat. Genet, 29, 418, 10.1038/ng747 · DOI · Paper page
  73. Xu, 2001, Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis, Nat. Genet, 28, 266, 10.1038/90108 · DOI · Paper page
  74. Xu, 1999, Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation, Nat. Genet, 22, 37, 10.1038/8743 · DOI · Paper page
  75. Blyth, 1995, Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss, Oncogene, 10, 1717
  76. Elson, 1995, The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice, Oncogene, 11, 181
  77. Curtis, 1997, The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice, Oncogene, 15, 2975, 10.1038/sj.onc.1201467 · doi:10.1038/sj.onc.1201467
  78. Brodie, 2001, Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis, Oncogene, 20, 1445, 10.1038/sj.onc.1204222 · DOI
  79. Donehower, 1995, Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability, Genes Dev., 9, 882, 10.1101/gad.9.7.882 · DOI · Paper page
  80. Hundley, 1997, Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53, Mol. Cell Biol., 17, 723, 10.1128/MCB.17.2.723 · DOI · Paper page
  81. Marin, 1994, Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis, Oncogene, 9, 3107
  82. Harvey, 1995, Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin, Cancer Res, 55, 1146
  83. Williams, 1994, Cooperative tumorigenic effects of germline mutations in Rb and p53, Nat. Genet, 7, 480, 10.1038/ng0894-480 · DOI · Paper page
  84. Knudson, 2001, Bax accelerates tumorigenesis in p53-deficient mice, Cancer Res, 61, 659
  85. Hosokawa, 2001, In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53, Transgenic Res, 10, 471, 10.1023/A:1012064911751 · doi:10.1023/a:1012064911751
  86. Cichowski, 1999, Mouse models of tumor development in neurofibromatosis type 1, Science, 286, 2172, 10.1126/science.286.5447.2172 · DOI · Paper page
  87. Reilly, 2000, Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects, Nat. Genet, 26, 109, 10.1038/79075 · DOI · Paper page
  88. McClatchey, 1998, Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors, Genes Dev., 12, 1121, 10.1101/gad.12.8.1121 · DOI · Paper page
  89. Halberg, 2000, Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers, Proc. Natl. Acad. Sci. USA, 97, 3461, 10.1073/pnas.97.7.3461 · DOI · Paper page
  90. Wetmore, 2001, Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched, Cancer Res, 61, 513
  91. Artandi, 2000, Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice, Nature, 406, 641, 10.1038/35020592 · DOI · Paper page
  92. Cornelissen, 2019, Exogenous ERalpha Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice, J. Mammary Gland Biol. Neoplasia, 24, 305, 10.1007/s10911-019-09437-z · DOI
  93. Reuss, 2023, Simultaneous Nbs1 and p53 inactivation in neural progenitors triggers high-grade gliomas, Neuropathol. Appl. Neurobiol., 49, 10.1111/nan.12915 · DOI
  94. Carr, 2016, Mdm2 Phosphorylation Regulates Its Stability and Has Contrasting Effects on Oncogene and Radiation-Induced Tumorigenesis, Cell Rep., 16, 2618, 10.1016/j.celrep.2016.08.014 · DOI
  95. Macias, 2010, An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction, Cancer Cell, 18, 231, 10.1016/j.ccr.2010.08.007 · DOI · Paper page
  96. Meng, 2015, Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways, Oncogene, 34, 5709, 10.1038/onc.2015.39 · DOI
  97. Liu, 2017, Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis, Oncogene, 36, 1374, 10.1038/onc.2016.301 · DOI
  98. Pan, 2011, The in vivo role of the RP-Mdm2-p53 pathway in signaling oncogenic stress induced by pRb inactivation and Ras overexpression, PLoS One, 6, 10.1371/journal.pone.0021625 · DOI
  99. Cheng, 2010, Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis, Cancer Res, 70, 7684, 10.1158/0008-5472.CAN-09-3231 · DOI
  100. Han, 2022, PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective, Acta Mater. Med, 1, 244
  101. Bhatia, 2023, Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer, Curr. Med Chem., 30, 3668, 10.2174/0929867330666221114103924 · DOI
  102. Alaseem, 2023, Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens, Saudi Pharm. J., 31, 10.1016/j.jsps.2023.101790 · DOI
  103. Konopleva, 2020, MDM2 inhibition: an important step forward in cancer therapy, Leukemia, 34, 2858, 10.1038/s41375-020-0949-z · DOI · Paper page
  104. Rusiecki, 2019, MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present), Recent Pat. Anticancer Drug Discov., 14, 324, 10.2174/1574892814666191022163540 · DOI
  105. Cha, 2005, Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth, Cancer Res, 65, 2287, 10.1158/0008-5472.CAN-04-3250 · DOI · Paper page
  106. Rong, 2009, Gambogic acid down-regulates MDM2 oncogene and induces p21(Waf1/CIP1) expression independent of p53, Cancer Lett., 284, 102, 10.1016/j.canlet.2009.04.011 · DOI
  107. Lai, 2012, Aciculatin induces p53-dependent apoptosis via MDM2 depletion in human cancer cells in vitro and in vivo, PLoS One, 7, 10.1371/journal.pone.0042192 · DOI
  108. Jia, 2023, Ganoderic Acid A and Its Amide Derivatives as Potential Anti-Cancer Agents by Regulating the p53-MDM2 Pathway: Synthesis and Biological Evaluation, Molecules, 28, 10.3390/molecules28052374 · DOI
  109. Gao, 2020, Chemopreventive Agent 3,3′-Diindolylmethane Inhibits MDM2 in Colorectal Cancer Cells, Int J. Mol. Sci., 21, 10.3390/ijms21134642 · DOI
  110. Park, 2020, The Antiproliferative Activity of Oxypeucedanin via Induction of G(2)/M Phase Cell Cycle Arrest and p53-Dependent MDM2/p21 Expression in Human Hepatoma Cells, Molecules, 25
  111. Tin, 2014, Essential role of the cancer stem/progenitor cell marker nucleostemin for indole-3-carbinol anti-proliferative responsiveness in human breast cancer cells, BMC Biol., 12, 72, 10.1186/s12915-014-0072-6 · DOI
  112. Li, 2007, Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway, Cancer Res, 67, 1988, 10.1158/0008-5472.CAN-06-3066 · DOI · Paper page
  113. Gao, 2020, Inhibition of esophageal-carcinoma cell proliferation by genistein via suppression of JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways, Aging (Albany NY), 12, 6240, 10.18632/aging.103019 · DOI
  114. Li, 2005, Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels, Cancer Res, 65, 8200, 10.1158/0008-5472.CAN-05-1302 · DOI · Paper page
  115. Yu, 2020, Resveratrol promotes osteogenesis and alleviates osteoporosis by inhibiting p53, Aging (Albany NY), 12, 10359, 10.18632/aging.103262 · DOI
  116. Bekes, 2022, PROTAC targeted protein degraders: the past is prologue, Nat. Rev. Drug Discov., 21, 181, 10.1038/s41573-021-00371-6 · DOI · Paper page
  117. Liu, 2022, Targeting micro-environmental pathways by PROTACs as a therapeutic strategy, Semin Cancer Biol., 86, 269, 10.1016/j.semcancer.2022.07.001 · DOI
  118. Kelm, 2023, PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy, Mol. Cancer, 22, 62, 10.1186/s12943-022-01707-5 · DOI · Paper page
  119. Choudhary, 2023, Target protein degradation by protacs: A budding cancer treatment strategy, Pharm. Ther., 250, 10.1016/j.pharmthera.2023.108525 · DOI
  120. Inuzuka, 2022, PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives, Acta Mater. Med, 1, 24
  121. Wang, 2020, PhotoPROTACs: A Novel Biotechnology for Cancer Treatment, Trends Cell Biol., 30, 749, 10.1016/j.tcb.2020.08.003 · DOI
  122. Ahmad, 2023, Recent Advances in PROTAC-Based Antiviral Strategies, Vaccin. (Basel), 11
  123. He, 2024, Progress in the controllability technology of PROTAC, Eur. J. Med Chem., 265, 10.1016/j.ejmech.2023.116096 · DOI
  124. Chen, 2023, Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity, J. Med Chem., 66, 8428, 10.1021/acs.jmedchem.3c00302 · DOI · Paper page
  125. Rovers, 2023, Methods for computer-assisted PROTAC design, Methods Enzym., 690, 311, 10.1016/bs.mie.2023.06.020 · DOI
  126. Wurz, 2019, Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors, J. Med Chem., 62, 445, 10.1021/acs.jmedchem.8b01945 · DOI · Paper page
  127. Yang, 2023, Turning chiral peptides into a racemic supraparticle to induce the self-degradation of MDM2, J. Adv. Res, 45, 59, 10.1016/j.jare.2022.05.009 · DOI
  128. Adams, 2023, Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer, Cancer Discov., 13, 1210, 10.1158/2159-8290.CD-22-1131 · DOI · Paper page
  129. Peuget, 2023, MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation, Cancer Discov., 13, 1043, 10.1158/2159-8290.CD-23-0229 · DOI
  130. Wang, 2023, Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer, Bioorg. Chem., 131, 10.1016/j.bioorg.2022.106327 · DOI
  131. Qi, 2021, Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein, Bioorg. Chem., 111, 10.1016/j.bioorg.2021.104901 · DOI · Paper page
  132. Marcellino, 2023, An MDM2 degrader for treatment of acute leukemias, Leukemia, 37, 370, 10.1038/s41375-022-01735-6 · DOI
  133. Chen, 2022, Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression, Theranostics, 12, 6665, 10.7150/thno.75444 · DOI
  134. Cui, 2023, Synthesis and Antineoplastic Activity of a Dimer, Spiroindolinone Pyrrolidinecarboxamide, Molecules, 28, 10.3390/molecules28093912 · DOI
  135. Dong, 2009, Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway, Mol. Cancer, 8, 103, 10.1186/1476-4598-8-103 · DOI · Paper page
  136. Kogan-Sakin, 2011, Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells, Cell Death Differ., 18, 271, 10.1038/cdd.2010.94 · DOI
  137. Kong, 2023, Selective degradation of the p53-R175H oncogenic hotspot mutant by an RNA aptamer-based PROTAC, Clin. Transl. Med, 13, 10.1002/ctm2.1191 · DOI
  138. Chang, 2022, MDM2-BCL-X(L) PROTACs enable degradation of BCL-X(L) and stabilization of p53, Acta Mater. Med, 1, 333
  139. Armata, 2007, The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression, Cancer Res, 67, 11696, 10.1158/0008-5472.CAN-07-1610 · DOI · Paper page
  140. Koyama, 2023, Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study, Cancer Discov., 13, 1814, 10.1158/2159-8290.CD-23-0419 · DOI
  141. Gounder, 2023, A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas, J. Clin. Oncol., 41, 1714, 10.1200/JCO.22.01285 · DOI · Paper page
  142. Mascarenhas, 2022, The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study, Blood Adv., 6, 1162, 10.1182/bloodadvances.2021006043 · DOI
  143. Yan, 2021, A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity, Theranostics, 11, 6833, 10.7150/thno.59020 · DOI
  144. Billimoria, 2023, Senescence in cancer: Advances in detection and treatment modalities, Biochem Pharm., 215, 10.1016/j.bcp.2023.115739 · DOI
  145. Troiani, 2022, Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer, Nat. Commun., 13, 2177, 10.1038/s41467-022-29824-1 · DOI · Paper page
  146. Eberhart, 2023, Killing zombies: Senolytic therapy in pilocytic astrocytoma, Neuro Oncol., 25, 748, 10.1093/neuonc/noad016 · DOI
  147. Carpenter, 2021, Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy, Biochem Pharm., 193, 10.1016/j.bcp.2021.114765 · DOI
  148. Sasaki, 2020, FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer, Cancers (Basel), 12, 10.3390/cancers12102976 · DOI
  149. Chang, 2024, Senolysis Enabled by Senescent Cell-Sensitive Bioorthogonal Tetrazine Ligation, Angew. Chem. Int Ed. Engl., 63, 10.1002/anie.202315425 · DOI
  150. Toufektchan, 2018, The Guardian of the Genome Revisited: p53 Downregulates Genes Required for Telomere Maintenance, DNA Repair, and Centromere Structure, Cancers (Basel), 10, 10.3390/cancers10050135 · DOI · Paper page
  151. Horikawa, 2011, p53 governs telomere regulation feedback too, via TRF2, Aging (Albany NY), 3, 26, 10.18632/aging.100271 · DOI
  152. Chou, 2022, Sirtuin-1 attenuates cadmium-induced renal cell senescence through p53 deacetylation, Ecotoxicol. Environ. Saf., 245, 10.1016/j.ecoenv.2022.114098 · DOI
  153. Yang, 2019, Sirtuin 2 expression suppresses oxidative stress and senescence of nucleus pulposus cells through inhibition of the p53/p21 pathway, Biochem Biophys. Res Commun., 513, 616, 10.1016/j.bbrc.2019.03.200 · DOI
  154. Solary, 2022, Ageing and cancer: a research gap to fill, Mol. Oncol., 16, 3220, 10.1002/1878-0261.13222 · DOI
  155. Carroll, 2022, Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care, Nat. Rev. Clin. Oncol., 19, 173, 10.1038/s41571-021-00580-3 · DOI · Paper page

Cited by

Metadata

Authors
Huang, Y., Che, X., Wang, P. W., & Qu, X.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2024-06
Volume
101
Pages
44-57
ISSN
1044-579X
Cited by
94
References
51
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.